CYTH News and Press, Cyclo Therapeutics Inc. From 07/21/22

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...

Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol ® Cyclo™ Program Steering Committee and the Global Principal Investigator for the Company’s ongoing TransportNPC™ study evaluating Trappsol ® Cyclo™ for the tre...

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, tod...

Cyclo Therapeutics press release (NASDAQ:CYTH): Q1 GAAP EPS of -$0.33 beats by $0.14. Revenue of $0.19M (-47.2% Y/Y) misses by $0.36M. For further details see: Cyclo Therapeutics GAAP EPS of -$0.33 beats by $0.14, revenue of $0.19M misses by $0.36M

- Continued advancement of lead development program evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing global pivotal study (TransportNPC™) - Phase 2 study of Trappsol ® Cyclo™ for the treatment of Alzheimer&#...

– Live video webcast with moderated fireside chat with members of the Cyclo Therapeutics leadership team and Global Principal Investigator for the Phase 3 study, Professor Caroline Hastings, MD, on Monday, May 16 th at 2:00 PM ET Cyclo Therapeutics, Inc. (Nasd...

Oxidative stress contributes to the formation of misfolded amyloid and tau proteins and to neuroinflammation all of which can further increase oxidative stress. Drugs that target pro-inflammatory cytokines such as INmune Bio's XPro1595 and Montelukast are likely too specific and too l...

Efforts to manipulate growth factors including those being undertaken by Athira and Synaptogenix are unlikely to be successful because the pathway through which growth factors work is inhibited by nitration. Anti-amyloid treatments such as those being undertaken by Biogen and Eisai, E...

Cyclo Therapeutics Inc. (NASDAQ:CYTH) traded today at a new 52-week high of $17.60. This new high was reached on above average trading volume as 18.2 million shares traded hands, while the average 30-day volume is approximately 61,000 shares. Based on a current price of $2.95, Cyclo Ther...